References
- Proven A, Gabriel SE, Orces C, O’Fallon WM, Hunder GG. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum 2003;49:703–8.
- Durand M, Thomas SL. Incidence of infections in patients with giant cell arteritis: a cohort study. Arthritis Care Res 2012;64:581–8.
- Kermani TA, Ytterberg SR, Warrington KJ. Pneumocystis jiroveci pneumonia in giant cell arteritis: a case series. Arthritis Care Res 2011;63:761–5.
- Roig J, Gomez-Plaza C. [Fever of three weeks development in a 74 year-oldwoman with giant cell arteritis], in Spanish. Med Clin (Barc) 1994;103:150–6.
- Bella Cueto F, Costa Roma J, Gonzalez de Zarate P, Pujol Farriol R, Aguirre Errasti L, Martinez LdLJ. [Giant cell arteritis. Multicenter study of 100 cases with positive biopsies], in SpanishMed Clin (Barc) 1985;85:43–8.
- Kim HA, Yoo CD, Baek HJ, Lee EB, Ahn C, Han JS, Mycobacterium tuberculosis infection in a corticosteroid-treated rheumatic disease patient population. Clin Exp Rheumatol 1998;16:9–13.
- Andonopoulos AP, Safridi C, Karokis D, Bounas A. Is a purified protein derivative skin test and subsequent antituberculous chemoprophylaxis really necessary in systemic rheumatic disease patients receiving corticosteroids? Clin Rheumatol 1998;17:181–5.
- Cid MC, Font C, Coll-Vinent B, Grau JM. Large vessel vasculitides. Curr Opin Rheumatol 1998;10:18–28.
- Tal S, Guller V, Gurevich A, Levi S. Fever of unknown origin in the elderly. J Intern Med 2002;252:295–304.